

Henrik Stage Appointed Interim CEO of Santaris Pharma A/S

Hørsholm, Denmark, April 25th, 2012. — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that Søren Tulstrup, President and Chief Executive Officer, has decided to leave the company per April 30, 2012, to pursue other opportunities. Henrik Stage, Vice President and Chief Financial Officer of the Company, will take over as interim CEO

Dr. Flemming Ørnskov, Chairman of the Board of Directors stated: “I truly regret that Søren, in connection with the company’s recently completed restructuring, has decided to step down, and I want to thank Søren for his many successful achievements most notably entering into the strategic collaborations with Pfizer, Shire and Miragen and the advancement of the Company’s Miravirsen HCV drug candidate to phase 2 where it has shown very promising data.”

“I am also delighted that Henrik Stage has accepted to take over the role as interim CEO. Henrik knows Santaris Pharma from his 8 years of service as Chief Financial Officer, and is fully capable of leading Company through the next important stages of consolidation and growth”.

Before joining Santaris Pharma Henrik Stage held senior executive positions at Carlsberg, FLS Industries, Hempel and Hardy International, in Denmark, USA, Canada and Vietnam. He holds a Masters degree in Finance from the Copenhagen Business School, Denmark. Henrik Stage has been with Santaris Pharma since 2004.

About Santaris Pharma A/S

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Please visit www.santaris.com for more information

For further information please contact

Henrik Stage, CEO

Cell: +45 4026 0900

e-mail: hs@santaris.com

www.santaris.com